Table 2 Visual outcomes, follow-up and treatment of TINU patients.

From: Tubulointerstitial nephritis and uveitis in Northern Ireland

 

Snellen VA at presentation

Snellen VA at 1 year

Number of

Snellen VA at last follow-up

Current treatment

 

Right

Left

Right

Left

years of follow-up

Right

Left

1

6/9

6/6

6/6

6/6

4

6/6 − 1

6/7.5

Discharged

2

6/9

6/9

6/12

6/12

2

6/12

6/12

Predforte and oral Prednisolone 1 mg OD

3

6/18

6/9

6/18

6/12

5

6/12

6/15

Maxidex OD to both eyes. Awaiting left cataract surgery

4

6/6

6/5

6/6

6/6

16

6/7.5

6/6

Mycophenolate 1.5 g BD and Timolol 0.5% BD Right eye

5

6/6

6/6

6/6

6/5

4

6/7.5

6/5

Discharged

6

6/6

6/6

6/9 − 2

6/6

7

6/7.5

6/7.5

Mycophenolate 1.5 g BD, Prednisolone 5 mg OD, Humira alt weeks, Pred-forte, Mydrilate

7

6/5

6/5

6/6 + 4

6/5 − 3

9

6/5

6/5

Mycophenolate 1 gm BD

8

6/24

6/24

6/6 − 2

6/9 − 2

6

6/4.8

6/9.5

Methotrexate 15 mg weekly, Prednisolone 5 mg. Subtenon triamcinolone injection.

9

6/7.5

6/6

6/6 + 2

6/5

3

6/5

6/5

Sub Cut Humira 40 mg every 2 weeks

10

Not known

6/5

6/4

10

6/7.5

6/5

Discharged

11

6/6

6/5

6/6

6/4.8

3

6/6

6/5

Discharged

12

6/24

6/6

<1 Year since presentation

1

6/6

6/5

Discharged

13

6/6 + 2

6/6 + 3

6/9 + 1

6/9 − 1

8

6/9.5

6/5

Predsol 0.5% bd to both eyes

14

6/6

6/6

6/6 + 2

6/9 + 1

8

6/7.5

6/7.5

Mycophenolate. Prednisolone 5 mg OD. Orbital floor Kenalog injection.

15

6/4.8

6/4.8

<1 Year since presentation

0.25

6/4.8

6/4.8

Mycophenolate for eyes

16

6/5

6/5

<1 Year since presentation

0.33

6/4.8

6/4.8

Mycophenolate for eyes

17

6/7.5

6/7.5

6/7.5

6/7.5

1

6/19

6/7.5

Oral Prednisolone

18

6/6

6/5

6/5

6/5

10

6/12

6/9.5

Predforte twice a day and Ganfort once a day.

19

6/9

6/9

6/6

6/6

4

6/9

6/6

Discharged

20

6/6

6/6

6/6

6/6

3

6/5

6/5

Discharged

21

6/7.5

6/6

6/6

6/6

2

6/6

6/6

Lost to follow-up

22

6/6

6/6

6/6

6/6

1

6/4.8

6/6

Discharged

23

6/6

6/6

<1 Year since presentation

0.33

6/6

6/6

Discharged

24

6/7.6

6/7.6

<1 Year since presentation

0.33

6/7.6

6/7.6

Discharged

Back to article page